Henrietta NielsenLektor

Om mig

Henrietta M Nielsen, PhD
Lektor i neurokemi och molekylär neurobiologi
Senior Editor Molecular Neurodegeneration
Associate Editor Jounal of Alzheimer's Disease
Academic Editor PLOS One
Editorial Board member, Aging Brain
President of the International Society for Molecular Neurodegeneration (ISMND)

UTBILDNING

2000-2003
Lunds Universitet, Sverige
Leg. Biomedicinsk Analytiker

2003-2004
Kalmar Högskola, Sverige
Magisterexamen i biomedicin

2004-2007
Lunds Universitet, Sverige
Filosofie doktorsexamen i medicinska vetenskaper

TIDIGARE ANSTÄLLNINGAR

2002-2004
Blodcentralen, Skånes Universitetssjukhus i Lund, Sverige
Laboratorieassistent/BMA                                                              

2008-2009
VU University Medical Center, Amsterdam, the Netherlands     
Postdoc

2009-2012   
Luns Universitet, Institutionen för kliniska vetenskaper Malmö, Sverige
Biträdande forskare, postdoktor

2012-2014
Mayo Clinic, Jacksonville FL, USA
Research Associate/Instructor of neuroscience

2014-2015
Mayo Clinic, Jacksonville FL, USA
Assistant Professor of Neuroscience         

ADMINISTRATIVA UPPDRAG   

Förtroendevalda uppdrag

2002
Lunds Universitet, Lund, Sverige
Studeranderepresentant i styrelsen för Biomedicinska Analytikerprogrammet

2005-2007
Lunds Universitet, Lund, Sverige
Styrelseledamot i Doktorandkåren

2009-2010
Lunds Universitet, Lund, Sverige
Grundare av och styrelsemedlem LPS, Lund Postdoctoral Society

2010-2011
Lunds Universitet, Medicinska fakulteten, Lund, Sverige
Future Faculty projektadministratör

2018-
Stockholms Universitet, Stockholm, Sverige
Lärarrepresentant i institutionsstyrelsen Biokemi och Biofysik

2018-
Stockholms Universitet, Stockholm, Sverige
Experimental Core Facility styrkommittémedlem

Granskare av vetenskapliga manuskript inskickade för publicering i tidskrift

Annals of Anatomy, Current Alzheimer Research, GLIA, Neuroscience, Molecular Neurodegeneration, Biomarkers in Medicine, Molecular Autism, Acta Neuropathologica, Neuroscience & Biobehavioral Reviews, Neurobiology of disease, Neurology, PloS One, Journal of Neurology, Neurobiology of Aging, Journal of Alzheimer’s disease, Annals of Neurology, Aging Cell, Acta Neuropathologica Communications, Journal of Neuroscience, Scientific Reports, Translational Neurodegeneration, Science Advances, Acta Neurologica Belgica, Journal of Molecular Neuroscience

Redaktör för vetenskapliga tidskrifter
2012-01-12 -
Associate editor, Journal of Alzheimer’s disease

2012-03-05 -
Senior editor, Molecular Neurodegeneration

2018 - 
Academic editor, Plos One

Granskare av internationella forskningsanslagsansökningar

2013, 2019
AFI (ALZHEIMER FORSCHUNG INITIATIVE), Tyskland

2014
ZonMw - The Netherlands Organisation for Health Research and Development, Nederländerna          

2014
Alzheimer's Research, Storbritannien

2015, 2018
Alzheimer’s Society, Storbritannien

2016, 2017, 2018
Alzheimer’s Association, USA                                                                                                                   

ORGANISATION AV VETENSKAPLIGA INTERNATIONELLA KONFERENSER

2013
3rd International Conference on Molecular Neurodegeneration, Cannes, France

2016
4th International Conference on Molecular Neurodegeneration, Seoul, Korea

2018
5th International Conference on Molecular Neurodegeneration, Stockholm, Sweden

2020
6th International Conference on Molecular Neurodegeneration, Bangkok, Thailand
https://www.worldeventsforum.com/mn/ 

Doktorander

Anna Edlund
Daniel Twohig
Andreas Giannisis

VETENSKAPLIGA PUBLIKATIONER

Originalartiklar

1. Patra K, Giannisis A, Edlund AK, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Nielsen HM. Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease. 2019. Journal of Alzheimer's disease Sep 3. doi: 10.3233/JAD-190175.
2. Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, Nordberg A, White LR, Nielsen HM. The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease. 2018. Acta Neuropathologica Communications Nov 26;6(1):130.
3. Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, Grøntvedt GR, Bråthen G, Begcevic I, Moussaud S, Minthon L, Hansson O, Diamandis EP, White LR, Nielsen HMN. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. 2018. Alzheimer’s Research & Therapy. Jan 29;10(1):9
4. Schultz N, Brännström K, Byman E, Moussaud S, Nielsen HMN, the Netherlands Brain Bank, Olofsson A, Wennström M. Amyloid-beta 1-40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro. 2018. Aging Cell. Jun;17(3):e12728
5. Ogaki K, Martens YA, Heckman MG, Koga S, Walton RL, Soto-Ortolaza AI, Vargas E, Nielsen HMN, Fujioka S, Uitti RJ, Kanekiyo T, Wszolek ZK, Low PA, Singer W, Dickson DW, Bu G, Ross OA. Multiple system atrophy and apolipoprotein E. 2018. Movement Disorders Apr;33(4):647-650
6. Nielsen HM, Chen K, Lee W, Chen Y, Bauer RJ, 3rd, Reiman E, et al. Peripheral apoE isoform levels in cognitively normal APOE epsilon3/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. 2017. Alzheimer's Research & Therapy. Jan 30;9(1):5
7. Fu Y, Zhao J, Atagi Y, Nielsen HM, Liu CC, Zheng H, Shinohara M, Kanekiyo T, Bu G. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. 2016. Molecular Neurodegeneration. May 5;11(1):37.
8. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. 2015. PLoS One. Aug 13;10(8):e0135458.
9. Hoozemans JJM, van Haastert ES, Mulder SD, Nielsen HM, Veerhuis R, Ruijtenbeek R, Rozemuller AJM, Hilhorts R, van der Vies SM. Increased IRAK-4 kinase activity in Alzheimer’s disease:  IRAK-1/4 inhibitor I prevents pro-inflammatory cytokine secretion but not uptake of amyloid beta by primary human glia. 2014. Journal of Clinical & Cellular Immunology. August 4: 5:4
10. Schultz N, Nielsen HM, Minthon L, Malin Wennström. Involvement of MMP-9 in Amyloid-beta 1-42 induced shedding of pericytic NG2. 2014. Journal of Neuropathology and Experimental Neurology.  Jul;73(7):684-92
11. Zhao J, Fu Y, Liu-C-C, Shinohara M, Nielsen HM, Dong Q, Kanekiyo T, Bu G. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the RXR/RAR pathway. 2014. Journal of Biological Chemistry. Apr 18;289(16):11282-92
12. Wennström M, Nielsen  HM,  Orhan F, Londos E, Minthon L, Erhardt S. Kynurenic acid levels in cerebrospinal fluid from patients with Alzheimer´s disease or dementia with Lewy bodies. 2014. International Journal of Tryptophan Research. 7: 1–7
13. Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. 2014. ACTA Neuropathologica. May;127(5):633-43
14. Martinez-Morillo E, Nielsen HM, Batruch I, Dabrovich AP, Begcevic I, Lopez MF, Minthon L, Bu G, Mattson N, Portelius E, Hansson O, Diamandis EP. Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. 2014. Journal of Proteome Research. Feb 7;13(2):1077
15. Mulder SD, Nielsen HM, Blankeinstein MA, Eikelenboom P, Veerhuis R. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. 2014. GLIA Apr;62(4):493-503
16. Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Minthon L, Hansson O, Wennström M. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. 2014. Journal of Alzheimer’s disease. Jan 1;40(2):343-50
17. Lindqvist D, Hall S, Surova S, Sporre O, Nielsen H, Janelidze S, Brundin L, Hansson O. Cerebrospinal fluid inflammatory markers in Parkinson´s disease - associations with depression, fatigue, and cognitive impairment. 2013. Brain, behavior, and immunity. Oct;33:183-9
18. Nielsen HM, Ek D, Avdic U, Orbjörn C, Hansson O,The Netherlands Brain Bank, Veerhuis R,
    Rozemuller AJM, Brun A, Minthon L, Wennström M. NG2 cells, a new trail for Alzheimer’s disease mechanisms? 2013. Acta Neuropathologica Communications May 9;1(1):7
19. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. Low levels of neurosin and its substrate α-synuclein in patients with synucleinopathy. 2013. PLoS One. 2013;8(1):e53250. Epub 2013 Jan 8
20. Westin K, Buchave P, Nielsen HM, Minthon L, Janciauskiene S, Hansson O. High levels of CCL2 are associated with faster cognitive decline in prodromal Alzheimer’s disease. 2012. PLoS One. 2012;7(1):e30525. Epub 2012 Jan 30
21. Wennström M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and α-synuclein levels in dementia patients. 2012. Journal of Alzheimer’s Disease Jan 1;29(1):125-32.
22. Nielsen HM, Palmqvist S, Minthon L, Londos E, Wennström M. Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia. 2012. Current Alzheimer Research. Mar 1;9(3):257-66
23. Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM. The effect of amyloid associated proteins on the expression of genes involved in amyloid clearance by adult human astrocytes. 2012. Experimental Neurology Jan;233(1):373-9. Epub 2011 Nov 10
24. Nielsen HM, Mulder SD, Beliën JAM, Musters RJP, Eikelenboom P, Veerhuis R. Astrocytic Aβ1-42 uptake is determined by Aβ-aggregation state and the presence of amyloid-associated proteins. 2010. Glia. 58(10):1235-46.
25. Nielsen HM, Veerhuis R, Holmqvist B, Janciauskiene S. Binding and uptake of Abeta1-42 by primary human astrocytes in vitro. 2009. Glia 57(9):978-88
26. Trouw LA, Nielsen HM, Minthon L, Londos E, Landberg G, Veerhuis R, Janciauskiene S, Blom AM. C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. 2008. Molecular Immunology 45(13):3649-60
27. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. 2007. Neurology 69(16):1569-1579
28. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. 2007. Neurobiology of Disease 26(1):27-35
29. Baker C, Nielsen HM, Minthon L, Wright HT, Chappell S, Okyere J, May S, Morgan K, Kalsheker N, Janciauskiene SM. 2007. Effects of Alzheimer's peptide and alpha1-antichymotrypsin on astrocyte gene expression. Neurobiology of Aging 28(1):51-61

Översiktsartiklar

1. Twohig D, Nielsen HM. α-synuclein in the pathophysiology of Alzheimer's disease. 2019. Molecular Neurodegeneration Jun 11;14(1):23
2. Wennström M, Nielsen HM. Cell adhesion molecules in Alzheimer’s disease. 2012. Degenerative Neurological and Neuromuscular Disease. July 4;2012(2):65-77
3. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. 2011. Molecular Immunology 48(14):1592-603

Bokkapitel

1. Carrasquillo MM, Bu G, Nielsen HM. 2012. Chapter 2: Apolipoprotein E. ‘Genetic Variants in Alzheimer's Disease’ edited by Carrasquillo and Morgan. Springer NY. June 30, 2013. ISBN 978-1-4614-7308-4

Forskningsprojekt

Pågående

Avslutade

Alzheimers sjukdom är ett fett( )problem